middle.news
Cleo’s ovarian cancer test clears first screening hurdle with strong Stage I results
9:03am on Wednesday 21st of October, 2026 AEDT
•
Healthcare
Read Story
Cleo’s ovarian cancer test clears first screening hurdle with strong Stage I results
9:03am on Wednesday 21st of October, 2026 AEDT
Key Points
Stage I sensitivity and specificity of 92.2% and 98.7% in high-risk screening
General population Stage I performance of 75.0% sensitivity and 100.0% specificity
AUC of 0.99 for Stage I cancers versus 0.87 for CA125
Larger independent and prospective studies are the next development hurdles
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE